E-ISSN 0976-2779 | ISSN 0975-8453
 

Review Article 


Alirocumab in Combination with Statins for CVD Risk Reduction: An Evidential Review

Roopa Basutkar Satyanarayan, Hema Siva, Tsundue Tenzin, Rayes Ahmed, Raja Durai, Sivasankaran Ponnusankar.

Abstract
Cardiovascular disorders have been one of the mainstay causes for the estimated rise in the incidences of mortality. In earlier times, treatment approach was initiated with statin therapy even though there were high reports of adverse events and failure to attain the target lipid concentration. In 2003, Proprotein Convertase subtilisin/kexin 9 was found to be responsible for the degradation and inactivation of LDL receptors. Ever since the concept was introduced, many researches have been conducted in this field for a better control in lipid management. Alirocumab was approved by
FDA in the year 2015 as a PCSK9 inhibitor indicated for heterozygous familial
hypercholesterolemia. The purpose of this review is to compile the available information on the LDL-C reduction capacity of Alirocumab in combination with statins and simultaneous cardiovascular risk reduction. It also aims at providing an evidential safety data associated with Alirocumab use.
Alirocumab is presently available in doses of 75 and 150mg subcutaneous injections once every two weeks. It is a monoclonal antibody directed
against PCSK9 and evidential data provides an estimate of about 54%
reduction in LDL-C concentrations. The application of Alirocumab as add on therapy to statins is the area of interest and the data suggests that there is a significant higher rate of LDL-C reductions in turn leading to a noteworthy
cardiovascular risk reduction. However the appropriate dose of statins to incorporate a PCSK9 inhibitor requires further hypotheses. Additionally the safety profile of Alirocumab was found to be comparable with placebo or the control.

Key words: Alirocumab, Atherosclerotic cardio vascular disease, Hypercholesterolemia, LDL-cholesterol, LDL-receptor, PCSK9 inhibition.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Roopa Basutkar Satyanarayan
Articles by Hema Siva
Articles by Tsundue Tenzin
Articles by Rayes Ahmed
Articles by Raja Durai
Articles by Sivasankaran Ponnusankar
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Roopa Basutkar Satyanarayan, Hema Siva, Tsundue Tenzin, Rayes Ahmed, Raja Durai, Sivasankaran Ponnusankar. Alirocumab in Combination with Statins for CVD Risk Reduction: An Evidential Review. SRP. 2019; 10(1): 32-41. doi:10.5530/srp.2019.1.6


Web Style

Roopa Basutkar Satyanarayan, Hema Siva, Tsundue Tenzin, Rayes Ahmed, Raja Durai, Sivasankaran Ponnusankar. Alirocumab in Combination with Statins for CVD Risk Reduction: An Evidential Review. http://www.sysrevpharm.org//?mno=302644532 [Access: June 01, 2020]. doi:10.5530/srp.2019.1.6


AMA (American Medical Association) Style

Roopa Basutkar Satyanarayan, Hema Siva, Tsundue Tenzin, Rayes Ahmed, Raja Durai, Sivasankaran Ponnusankar. Alirocumab in Combination with Statins for CVD Risk Reduction: An Evidential Review. SRP. 2019; 10(1): 32-41. doi:10.5530/srp.2019.1.6



Vancouver/ICMJE Style

Roopa Basutkar Satyanarayan, Hema Siva, Tsundue Tenzin, Rayes Ahmed, Raja Durai, Sivasankaran Ponnusankar. Alirocumab in Combination with Statins for CVD Risk Reduction: An Evidential Review. SRP. (2019), [cited June 01, 2020]; 10(1): 32-41. doi:10.5530/srp.2019.1.6



Harvard Style

Roopa Basutkar Satyanarayan, Hema Siva, Tsundue Tenzin, Rayes Ahmed, Raja Durai, Sivasankaran Ponnusankar (2019) Alirocumab in Combination with Statins for CVD Risk Reduction: An Evidential Review. SRP, 10 (1), 32-41. doi:10.5530/srp.2019.1.6



Turabian Style

Roopa Basutkar Satyanarayan, Hema Siva, Tsundue Tenzin, Rayes Ahmed, Raja Durai, Sivasankaran Ponnusankar. 2019. Alirocumab in Combination with Statins for CVD Risk Reduction: An Evidential Review. Systematic Reviews in Pharmacy, 10 (1), 32-41. doi:10.5530/srp.2019.1.6



Chicago Style

Roopa Basutkar Satyanarayan, Hema Siva, Tsundue Tenzin, Rayes Ahmed, Raja Durai, Sivasankaran Ponnusankar. "Alirocumab in Combination with Statins for CVD Risk Reduction: An Evidential Review." Systematic Reviews in Pharmacy 10 (2019), 32-41. doi:10.5530/srp.2019.1.6



MLA (The Modern Language Association) Style

Roopa Basutkar Satyanarayan, Hema Siva, Tsundue Tenzin, Rayes Ahmed, Raja Durai, Sivasankaran Ponnusankar. "Alirocumab in Combination with Statins for CVD Risk Reduction: An Evidential Review." Systematic Reviews in Pharmacy 10.1 (2019), 32-41. Print. doi:10.5530/srp.2019.1.6



APA (American Psychological Association) Style

Roopa Basutkar Satyanarayan, Hema Siva, Tsundue Tenzin, Rayes Ahmed, Raja Durai, Sivasankaran Ponnusankar (2019) Alirocumab in Combination with Statins for CVD Risk Reduction: An Evidential Review. Systematic Reviews in Pharmacy, 10 (1), 32-41. doi:10.5530/srp.2019.1.6





Most Viewed Articles
  • Dental Development between Assisted Reproductive Therapy (Art) and Natural Conceived Children: A Comparative Pilot Study
    Norzaiti Mohd Kenali, Naimah Hasanah Mohd Fathil, Norbasyirah Bohari, Ahmad Faisal Ismail, Roszaman Ramli
    SRP. 2020; 11(1): 01-06
    » Abstract » doi: 10.5530/srp.2020.1.01

  • Psychometric properties of the World Health Organization Quality of life instrument, short form: Validity in the Vietnamese healthcare context
    Trung Quang Vo*, Bao Tran Thuy Tran, Ngan Thuy Nguyen, Tram ThiHuyen Nguyen, Thuy Phan Chung Tran
    SRP. 2020; 11(1): 14-22
    » Abstract » doi: 10.5530/srp.2020.1.03

  • A Prospective Review on Phyto-Pharmacological Aspects of Andrographis paniculata
    Govindraj Akilandeswari, Arumugam Vijaya Anand, Palanisamy Sampathkumar, Puthamohan Vinayaga Moorthi, Basavaraju Preethi
    SRP. 2019; 10(1): 15-19
    » Abstract » doi: 10.5530/srp.2019.1.3

  • A Review of Pharmacoeconomics: the key to “Healthcare for All”
    Hasamnis AA, Patil SS, Shaik Imam, Narendiran K
    SRP. 2019; 10(1): s40-s42
    » Abstract » doi: 10.5530/srp.2019.1s.21

  • Deuterium Depleted Water as an Adjuvant in Treatment of Cancer
    Anton Syroeshkin, Olga Levitskaya, Elena Uspenskaya, Tatiana Pleteneva, Daria Romaykina, Daria Ermakova
    SRP. 2019; 10(1): 112-117
    » Abstract » doi: 10.5530/srp.2019.1.19

  • Most Downloaded
  • Dental Development between Assisted Reproductive Therapy (Art) and Natural Conceived Children: A Comparative Pilot Study
    Norzaiti Mohd Kenali, Naimah Hasanah Mohd Fathil, Norbasyirah Bohari, Ahmad Faisal Ismail, Roszaman Ramli
    SRP. 2020; 11(1): 01-06
    » Abstract » doi: 10.5530/srp.2020.1.01

  • Manilkara zapota (L.) Royen Fruit Peel: A Phytochemical and Pharmacological Review
    Karle Pravin P, Dhawale Shashikant C
    SRP. 2019; 10(1): 11-14
    » Abstract » doi: 0.5530/srp.2019.1.2

  • Pharmacognostic and Phytopharmacological Overview on Bombax ceiba
    Pankaj Haribhau Chaudhary, Mukund Ganeshrao Tawar
    SRP. 2019; 10(1): 20-25
    » Abstract » doi: 10.5530/srp.2019.1.4

  • A Review of Pharmacoeconomics: the key to “Healthcare for All”
    Hasamnis AA, Patil SS, Shaik Imam, Narendiran K
    SRP. 2019; 10(1): s40-s42
    » Abstract » doi: 10.5530/srp.2019.1s.21

  • A Prospective Review on Phyto-Pharmacological Aspects of Andrographis paniculata
    Govindraj Akilandeswari, Arumugam Vijaya Anand, Palanisamy Sampathkumar, Puthamohan Vinayaga Moorthi, Basavaraju Preethi
    SRP. 2019; 10(1): 15-19
    » Abstract » doi: 10.5530/srp.2019.1.3

  • Most Cited Articles